Defence's ARM-X Vaccine Shows Promising Results Against Ovarian Cancer in Pre-Clinical Trials

Defence Therapeutics Inc., a Canadian biopharmaceutical firm, announced that its ARM-X anti-cancer vaccine has demonstrated significant therapeutic effects against pre-established ovarian cancer in animal models. The vaccine, when combined with an anti-PD-1 immune-checkpoint inhibitor, resulted in complete responses in nearly all treated animals.

Using Defence’s Accum® platform, the ARM-X cells showed potent anti-tumoral responses, previously validated in models of solid T-cell lymphoma, melanoma, and pancreatic cancer. This study marked the fourth cancer type successfully targeted by the ARM-X vaccine, indicating its adaptability across different cancer types.

Defence CEO Sebastien Plouffe highlighted the vaccine's efficiency in requiring lower antigen amounts, thus avoiding the need for substantial tumor samples. The ARM-X vaccine’s versatility could set the stage for its use in personalized cancer treatment.

The company is expanding its research to test ARM-X on colon cancer and plans to initiate Phase I-IIa trials soon, focusing on its rapid and effective application across various malignancies.